Gamma‐Frequency Sensory Stimulation is Safe and Well‐Tolerated Treatment Option for Patients with Alzheimer’s Disease

Recent experimental findings demonstrate that sensory‐evoked brain gamma oscillation reduces Alzheimer’s disease (AD) pathologies in AD‐related transgenic mice, including decline in synaptic function, neurodegeneration, and brain atrophy (Adaikkan & Tsai, Trends Neurosci. 2020;43:24‐41). Based on these findings, gamma‐frequency sensory stimulation has been evaluated in multiple clinical trials, including the long‐term Overture a randomized, controlled trial (Clinicaltrials.gov: NCT03556280) assessing safety, tolerance, and efficacy of using Cognito Therapeutics medical device in patients with AD.